The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: A systematic review and meta-analysis

Annals of Internal Medicine

Volumn 164, Issue 7, 2016, Pages 472-478

  Collister, David ^a   Komenda, Paul ^a   Hiebert, Brett ^b   Gunasekara, Ravindi ^a   Xu, Yang ^a   Eng, Fredrick ^a   Lerner, Blake ^a   Macdonald, Kerry ^c   Rigatto, Claudio ^a   Tangri, Navdeep ^a  

^a Seven Oaks General Hospital   (Canada)

^b Cardiac Sciences Program   (Canada)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; CHRONIC KIDNEY DISEASE; DEPRESSION; EMOTION; FATIGUE; HEALTH; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MENTAL HEALTH; META ANALYSIS; PAIN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SOCIAL STATUS; SYSTEMATIC REVIEW; BLOOD; COMPLICATION; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

ANEMIA; HEMATINICS; HEMOGLOBINS; HUMANS; QUALITY OF LIFE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84962659559     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1839     Document Type: Review

References (42)

1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72: 247-59. [PMID: 17568785]
2. Canadian Institute for Health Information. Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012. Ottawa: Canadian Institute for Health Information; 2014.
3. United States Renal Data System, 2014 Annual Data Report: An Overview of the Epidemiology of Kidney Disease in the United States. Bethesda, Maryland: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
4. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13: 504-10. [PMID: 11805181]
5. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19: 121-32. [PMID: 14671047]
6. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153: 23-33. [PMID: 20439566] doi: 10.7326/0003-4819-153-1 -201007060-00252
7. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis. Cochrane Database Syst Rev. 2014;12: CD010590. [PMID: 25486075] doi: 10.1002/ 14651858.CD010590.pub2
8. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339: 584-90. [PMID: 9718377]
9. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355: 2085-98. [PMID: 17108343]
10. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355: 2071-84. [PMID: 17108342]
11. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006: CD003967. [PMID: 17054191]
12. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007; 369: 381-8. [PMID: 17276778]
13. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50: 471-530. [PMID: 17720528]
14. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2: 279-335.
15. U.S. Food and Drug Administration. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. June 2011. Accessed at www.fda.gov/Drugs/DrugSafety/ucm259639.htm on 26 November 2015.
16. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-32. [PMID: 19880844] doi: 10.1056/NEJMoa0907845
17. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25: 548-54. [PMID: 7702049]
18. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300: 573-8. [PMID: 2108751]
19. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on healthrelated quality of life for patients with chronic kidney disease: A systematic review and meta-analysis. Arch Intern Med. 2009;169: 1104-12. [PMID: 19546410] doi: 10.1001/archinternmed.2009.112
20. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. Am J Kidney Dis. 2010;55: 519-34. [PMID: 20031287] doi: 10.1053/j.ajkd.2009.09.019
21. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis. 2010;55: 535-48. [PMID: 20133033] doi: 10.1053/j.ajkd.2009.12.018
22. Johansen KL, Finkelstein FO, Revicki DA, Evans C, Wan S, Gitlin M, et al. Systematic review of the impact of erythropoiesisstimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012;27: 2418-25. [PMID: 22187314] doi: 10.1093/ndt/gfr697
23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151: 264-9. [PMID: 19622511]
24. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: D5928. [PMID: 22008217] doi: 10.1136/bmj.d5928
25. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26: 724-35. [PMID: 3393032]
26. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron. 1992;60: 302-6. [PMID: 1565182]
27. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics. 2000;18: 419-23. [PMID: 11151395]
28. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10: 407-15. [PMID: 2691207]
29. Weisstein EW. Normal difference distribution. Wolfram Math- World. Accessed at http://mathworld.wolfram.com/NormalDifference Distribution.html on 26 November 2015.
30. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik- Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14: 25. [PMID: 24548571] doi: 10.1186/1471-2288-14-25
31. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21: 1539-58. [PMID: 12111919]
32. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46: 799-811. [PMID: 16253719]
33. Foley RN, Parfrey PS, Morgan J, BarréPE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58: 1325-35. [PMID: 10972697]
34. Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, et al; TREAT Investigators. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: A randomized trial. Clin J Am Soc Nephrol. 2011;6: 845-55. [PMID: 21212421] doi: 10.2215/CJN.06450710
35. Roger SD, Jassal SV, Woodward MC, Soroka S, McMahon LP. A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE. Int Urol Nephrol. 2014;46: 469-75. [PMID: 23982766] doi: 10.1007/s11255-013-0512-1
36. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15: 141-55. [PMID: 10351188]
37. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82: 235-41. [PMID: 22437411] doi: 10.1038/ki.2012.76
38. Jassal SV, Chiu E, Hladunewich M. Loss of independence in patients starting dialysis at 80 years of age or older [Letter]. N Engl J Med. 2009;361: 1612-3. [PMID: 19828543] doi: 10.1056/NEJMc 0905289
39. Murtagh FE, Addington-Hall JM, Higginson IJ. End-stage renal disease: A new trajectory of functional decline in the last year of life. J Am Geriatr Soc. 2011;59: 304-8. [PMID: 21275929] doi: 10.1111/j.1532-5415.2010.03248.x
40. National Institute for Health and Care Excellence. Chronic kidney disease: Managing anemia. June 2015. Accessed at www.nice.org.uk/guidance/ng8 on 19 January 2016.
41. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: Systematic review and economic evaluation [technology report number 106]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
42. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75: 15-24. [PMID: 18813284] doi: 10.1038/ki.2008.414